Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

Assenagon Asset Management S.A. boosted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 53.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 856,572 shares of the biotechnology company’s stock after acquiring an additional 296,700 shares during the period. Assenagon Asset Management S.A. owned 1.73% of REGENXBIO worth $6,621,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC boosted its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC boosted its holdings in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the last quarter. GAMMA Investing LLC grew its position in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of REGENXBIO in the 3rd quarter valued at about $140,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

RGNX has been the subject of a number of analyst reports. Raymond James restated an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of REGENXBIO in a research note on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.27.

REGENXBIO Stock Up 3.1 %

Shares of RGNX opened at $7.37 on Monday. REGENXBIO Inc. has a twelve month low of $6.56 and a twelve month high of $28.80. The stock has a market capitalization of $365.11 million, a P/E ratio of -1.47 and a beta of 1.28. The company has a 50 day moving average of $8.72 and a 200-day moving average of $10.48.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.